-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | KY61559X1045 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 3B |
|---|---|
| PE Ratio | None |
| Target Price | 78.3077 |
| Beta | 1.23 |
| Dividend Yield | None |
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MLTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025